Sakunthala Muthugounder
Overview
Explore the profile of Sakunthala Muthugounder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
347
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jambon S, Sun J, Barman S, Muthugounder S, Bito X, Shadfar A, et al.
Blood Cancer Discov
. 2024 Dec;
6(1):55-72.
PMID: 39624992
Our study demonstrates the use of "IF-THEN" SynNotch-gated CAR-T cells targeting CD33 and CD123 in AML reduces off-tumor toxicity. This strategy enhances T-cell phenotype, improves expansion, preserves HSPCs, and mitigates...
2.
Louault K, Porras T, Lee M, Muthugounder S, Kennedy R, Blavier L, et al.
Oncoimmunology
. 2022 Dec;
11(1):2146860.
PMID: 36479153
Tumor-associated macrophages (TAM) and cancer-associated fibroblasts (CAF) and their precursor mesenchymal stromal cells (MSC) are often detected together in tumors, but how they cooperate is not well understood. Here, we...
3.
Tibbetts R, Yeo K, Muthugounder S, Lee M, Jung C, Porras-Corredor T, et al.
Cancer Immunol Immunother
. 2021 May;
71(1):153-164.
PMID: 34043024
Neuroblastoma (NBL) accounts for a disproportionate number of deaths among childhood malignancies despite intensive multimodal therapy that includes antibody targeting disialoganglioside GD2, a NBL antigen. Unfortunately, resistance to anti-GD2 immunotherapy...
4.
Shirinbak S, Chan R, Shahani S, Muthugounder S, Kennedy R, Hung L, et al.
Oncoimmunology
. 2021 Jan;
10(1):1838140.
PMID: 33489468
Immune checkpoint therapy has resulted in minimal clinical response in many pediatric cancers. We sought to understand the influence of immune checkpoint inhibition using anti-PD-1 and anti-CTLA-4 antibodies individually, in...
5.
Moghimi B, Muthugounder S, Jambon S, Tibbetts R, Hung L, Bassiri H, et al.
Nat Commun
. 2021 Jan;
12(1):511.
PMID: 33479234
The ability to utilize preclinical models to predict the clinical toxicity of chimeric antigen receptor (CAR) T cells in solid tumors is tenuous, thereby necessitating the development and evaluation of...
6.
Hadjidaniel M, Muthugounder S, Hung L, Sheard M, Shirinbak S, Chan R, et al.
Oncotarget
. 2017 Dec;
8(53):91516-91529.
PMID: 29207662
Tumor-associated macrophages (TAMs) are strongly associated with poor survival in neuroblastomas that lack amplification. To study TAM action in neuroblastomas, we used a novel murine model of spontaneous neuroblastoma lacking...
7.
Bluml S, Margol A, Sposto R, Kennedy R, Robison N, Vali M, et al.
Neuro Oncol
. 2015 Aug;
18(1):126-31.
PMID: 26254476
Background: Medulloblastomas in children can be categorized into 4 molecular subgroups with differing clinical characteristics, such that subgroup determination aids in prognostication and risk-adaptive treatment strategies. Magnetic resonance spectroscopy (MRS)...
8.
Ravindranath M, Ramasamy V, Moon S, Ruiz C, Muthugounder S
Evid Based Complement Alternat Med
. 2008 Oct;
6(4):523-30.
PMID: 18955299
We previously reported that catechins of green tea have different antiproliferative effects on cell lines derived from gender-dependent cancers; epicatechin 3-gallate (ECG) had the strongest inhibitory effect. In the present...
9.
Ravindranath M, Muthugounder S, Presser N
Melanoma Res
. 2008 Jan;
18(1):47-55.
PMID: 18227708
The primary cutaneous melanoma initially migrates to the regional lymph nodes (LNs). Human melanoma overexpresses gangliosides, the sialylglycosphingolipids. The ganglioside signatures may differ between primary and LN melanomas owing to...
10.
Ravindranath M, Muthugounder S, Hannah M, Morton D
Ann N Y Acad Sci
. 2007 Sep;
1107:212-22.
PMID: 17804549
Gangliosides expressed by solid malignancies are shed into the circulation at a rate that varies with tumor stage, burden, and progression. Gangliosides have an immunosuppressive effect; thus an increase in...